CODE REVISER USE ONLY

PROPOSED RULE MAKING

CR-102 (June 2024) (Implements RCW 34.05.320)

Do NOT use for expedited rule making

OFFICE OF THE CODE REVISER STATE OF WASHINGTON FILED

DATE: November 02, 2024 TIME: 2:09 PM

WSR 24-22-100

Agency: Department of Health

Original Notice

□ Supplemental Notice to WSR

□ Continuance of WSR

Preproposal Statement of Inquiry was filed as WSR 24-14-096; or

□ Expedited Rule Making--Proposed notice was filed as WSR _____; or

□ Proposal is exempt under RCW 34.05.310(4) or 34.05.330(1); or

Proposal is exempt under RCW _____

Title of rule and other identifying information: (describe subject) Medical assistant medication administration requirements and apprenticeship programs. The Department of Health (department) is proposing rule amendments to WAC 246-827-0010, 246-827-0200, and 246-827-0240 to align with statutes updated by Engrossed Substitute House Bill (ESHB) 1073 (chapter 134, Laws of 2023) and Engrossed Substitute Senate Bill (ESSB) 5983 (chapter 248, Laws of 2024) and to ensure that the rules are current and align with best practices. The department is also proposing a new section, WAC 246-827-0340, to address the medication administration requirements for the medical assistant-registered credential.

Hearing location(s):

Date:	Time:	Location: (be specific)		Comr	nent:
December 18, 2024		In-Person: WA State Department of Health Town Center 2 Room 166/167 111 Israel Rd SE Tumwater, Washington 98501 Zoom Link: Register in advance for this webinar https://us02web.zoom.us/webinar/re tzxOMYUR3yDXF7vp1jrqg After registering, you will receive a containing information about joining	gister/WN_	hybric attenc locatic writing	Pepartment of Health will be offering a I public hearing. Participants may I virtually or in-person at the physical on. You may also submit comments in g.
Date of intended adoption: 12/26/2024 (Note: This is NOT the effective date)					
Submit written comments to:			Assistar	ce for person	is with disabilities:
Name B	Name Becky McElhiney		Contact	Becky McElh	iney
Address P	O Box 4	7852 Olympia, WA 98504-7852	Phone	360-236-476	6
Email ht	tps://fort	ress.wa.gov/doh/policyreview	Fax	360-236-290	1
Fax 36	60-236-2	850	TTY	711	
Other			Email	medical.assi	stants@doh.wa.gov
Beginning (date and time) The date and time of this filing			Other		
By (date and time) December 18, 2024 at 11:59 PM			By (date)	December 4,	2024
passed ESHB	1073 wh	sal and its anticipated effects, incluic ich updated the supervision requirem ment is proposing amendments to me	ents and the	scope of prac	ctice for medical assistants in RCW

18.360.050 and establish requirements for medication administration by a medical assistant-registered (MA-R) credential.

The ESHB 1073 amendments to RCW 18.360.050 significantly expanded the scope of practice for the MA-R credential, specifically for medication administration. A new rule section is necessary to provide guidance regarding routes and supervision levels related to these tasks. The department is also proposing updates to the medical assistant-certified (MA-C) medication administration rules to align with ESHB 1073.

In 2024 the legislature passed ESSB 5983 which amended RCW 18.360.050 and lowered the supervision level required for MA-C and MA-Rs to provide treatment for known or suspected syphilis infections from "immediate or direct" visual supervision to "telemedicine" supervision. The department is proposing updates to the medication administration rules for MA-C and adding rule language in the new MA-R section to align with this supervision requirement change.

The department is also proposing an update to the MA-C training and certification requirements that clarify the types of apprenticeship programs that are accepted to meet training requirements.

Reasons supporting proposal: The proposal aligns rules with RCW 18.360.050 and provides clarity to licensees and the public regarding requirements for medication administration, supervision, and training requirements for medical assistants.

Statutory authority for adoption: RCW 18.360.030, Engrossed Substitute House Bill 1073 (chapter 134, Laws of 2023),						
and Engrossed Substitute Senate Bill 5983 (chapter 248, Laws of 2024) Statute being implemented: RCW 18.360.010, 18.360.040, and 18.360.050						
	Is rule necessary because of a:					
Federal L			🗆 Yes 🖂 No			
If yes, CITATIO						
		s, if any, as to statutory language, implementation, e	enforcement and fiscal			
matters: None			, and nood			
	nent: (person or organizat nent: □ Private. □ Public	ion) Department of Health ⊠ Governmental.				
Name of agenc	y personnel responsible	for:				
	Name	Office Location	Phone			
Drafting	Becky McElhiney	111 Israel Rd SE, Tumwater WA 98501	360-236-4766			
Implementation	James Chaney	111 Israel Rd SE, Tumwater WA 98501	360-236-2831			
Enforcement	James Chaney	111 Israel Rd SE, Tumwater WA 98501	360-236-2831			
If yes, insert sta The public m Name Addre Phone Fax TTY Email Other	tement here: hay obtain a copy of the scl ss	nool district fiscal impact statement by contacting:	□ Yes ⊠ No			
Is a cost-benefit analysis required under <u>RCW 34.05.328</u> ? Yes: A preliminary cost-benefit analysis may be obtained by contacting:						
Name						
Addre		mpia, WA 98504-7852				
Phone	-					
Fax	360-236-2850					
TTY	711					
Email	medical.assistants	⊉doh.wa.gov				
Other						
□ No:	□ No: Please explain:					

Regulatory Fairness Act and Small Business Economic Impact Statement Note: The <u>Governor's Office for Regulatory Innovation and Assistance (ORIA)</u> provides support in completing this part.					
This rule pro			requirements of the Regulatory Fairness Act (see sult the exemption guide published by ORIA. Please		
adopted sol regulation the adopted.	e proposal, or portions of the proposal, is exempt a ely to conform and/or comply with federal statute his rule is being adopted to conform or comply with description:	or regul			
	•	pecause	e the agency has completed the pilot rule process		
□ This rule	<u>RCW 34.05.313</u> before filing the notice of this property proposal, or portions of the proposal, is exempt us a referendum.		ule. ne provisions of <u>RCW 15.65.570</u> (2) because it was		
	e proposal, or portions of the proposal, is exempt ι	under R	CW 19.85.025(3). Check all that apply:		
	<u>RCW 34.05.310</u> (4)(b)		<u>RCW 34.05.310</u> (4)(e)		
	(Internal government operations)		(Dictated by statute)		
	RCW 34.05.310 (4)(c)		<u>RCW 34.05.310</u> (4)(f)		
	(Incorporation by reference)		(Set or adjust fees)		
	<u>RCW 34.05.310</u> (4)(d)		<u>RCW 34.05.310</u> (4)(g)		
	(Correct or clarify language)		((i) Relating to agency hearings; or (ii) process		
			requirements for applying to an agency for a license or permit)		
⊠ This rule	e proposal, or portions of the proposal, is exempt u	under R	CW 19.85.025(4). (Does not affect small businesses).		
□ This rule	e proposal, or portions of the proposal, is exempt u	under R	CW		
		posed	rule: The proposed rules impact individual licensees and		
not small bu					
(2) Scope of exemptions: Check one. ☑ The rule proposal: Is fully exempt. (Skip section 3.) Exemptions identified above apply to all portions of the rule proposal. □ The rule proposal: Is partially exempt. (Complete section 3.) The exemptions identified above apply to portions of the rule proposal, but less than the entire rule proposal. Provide details here (consider using this template from ORIA):					
□ The rule proposal: Is not exempt. (Complete section 3.) No exemptions were identified above.					
(3) Small business economic impact statement: Complete this section if any portion is not exempt.					
	If any portion of the proposed rule is not exempt , does it impose more-than-minor costs (as defined by RCW 19.85.020(2)) on businesses?				
 No Briefly summarize the agency's minor cost analysis and how the agency determined the proposed rule did not impose more-than-minor costs. Yes Calculations show the rule proposal likely imposes more-than-minor cost to businesses and a small business economic impact statement is required. Insert the required small business economic impact statement here: 					
The public may obtain a copy of the small business economic impact statement or the detailed cost calculations by contacting:					
	Name				
Address					
Phone					
Fax TTY					
Email					
	Other				

Name: Kristen Peterson, JD for Umair A. Shah, MD, MPH

Title: Chief of Policy for Secretary of Health

Signature: Kistinfulison

AMENDATORY SECTION (Amending WSR 23-16-004, filed 7/19/23, effective 8/19/23)

WAC 246-827-0010 Definitions. The following definitions apply throughout this chapter unless the context clearly indicates otherwise:

(1) "Controlled substance" has the same meaning as RCW 69.50.101.

(2) "Direct visual supervision" means the supervising health care practitioner is physically present and within visual range of the medical assistant.

(((2))) (3) "Forensic blood draw" means a blood sample drawn at the direction of a law enforcement officer for the purpose of determining its alcoholic or drug content by a person holding one of the credentials listed in RCW 46.61.506, including a medical assistantcertified, medical assistant-phlebotomist, or forensic phlebotomist.

(((3))) (4) "Health care practitioner" means a physician licensed under chapter 18.71 RCW; an osteopathic physician and surgeon licensed under chapter 18.57 RCW; or acting within the scope of their respective licensure, a podiatric physician and surgeon licensed under chapter 18.22 RCW, a registered nurse or advanced registered nurse practitioner licensed under chapter 18.79 RCW, a naturopath licensed under chapter 18.36A RCW, a physician assistant licensed under chapter 18.71A RCW, or an optometrist licensed under chapter 18.53 RCW.

(((4))) (5) "Hemodialysis" is a procedure for removing metabolic waste products or toxic substances from the human body by dialysis.

(((5))) <u>(6)</u> "Immediate supervision" means the supervising health care practitioner is on the premises and available for immediate response as needed.

(((6))) <u>(7) "Immediately available" means the supervising health</u> care practitioner is available to arrive on the premises in a reasonable amount of time or for an immediate audio or video telephone consultation.

(8) "Legend drug" means any drug which is required by any applicable federal or state law or regulation to be dispensed on prescription only or is restricted to use by <u>health care</u> practitioners only.

 $((\frac{1}{7}))$ (9) "Medical assistant" without further qualification means a person credentialed under chapter 18.360 RCW as a:

- (a) Medical assistant-certified;
- (b) Medical assistant-registered;
- (c) Medical assistant-hemodialysis technician; and
- (d) Medical assistant-phlebotomist.

(((8))) <u>(10)</u> "Medical assistant-hemodialysis technician" means a patient care dialysis technician trained in compliance with federal requirements for end stage renal dialysis facilities.

(((9))) <u>(11) "Medication" means a legend drug, over-the-counter</u> <u>drug, vaccine, or Schedule III through V controlled substance.</u>

(12) "Secretary" means the secretary of the department of health or the secretary's designee.

(((10))) <u>(13)</u> "Telemedicine supervision" means the delivery of direct patient care under supervision by a health care practitioner provided through the use of interactive audio and video technology, permitting real-time communication between a medical assistant at the originating site and a health care practitioner off premises. "Teleme-dicine" does not include the use of audio-only telephone, facsimile, or electronic mail.

"Telemedicine supervision" also includes supervision of a medical assistant-certified or medical assistant registered through telemedicine technology for administering intramuscular injections for the purpose of treating a known or suspected syphilis infection in accordance with RCW 18.360.050.

AMENDATORY SECTION (Amending WSR 23-16-004, filed 7/19/23, effective 8/19/23)

WAC 246-827-0200 Medical assistant-certified—Training and examination. An applicant for a medical assistant-certified credential must meet the following requirements:

(1) Successful completion of one of the following medical assistant training programs:

(a) Postsecondary school or college program accredited by the Accrediting Bureau of Health Education Schools (ABHES) or the Commission of Accreditation of Allied Health Education Programs (CAAHEP);

(b) Postsecondary school or college accredited by a regional or national accrediting organization recognized by the U.S. Department of Education, which includes a minimum of 720 clock hours of training in medical assisting skills, including a clinical externship of no less than 160 hours;

(c) ((A registered)) An apprenticeship program ((administered by a department of the state of Washington)) registered and approved by the Washington state apprenticeship and training council unless the secretary determines that the apprenticeship program training or experience is not substantially equivalent to the standards of this state. The apprenticeship program shall ensure a participant who successfully completes the program is eligible to take one or more examinations identified in subsection (2) of this section;

(d) The secretary may approve an applicant who submits documentation that they completed postsecondary education with a minimum of 720 clock hours of training in medical assisting skills. The documentation must include proof of training in all of the duties identified in RCW 18.360.050(1) and a clinical externship of no less than 160 hours; or

(e) The secretary may approve an applicant who submits documentation that they completed a career and technical education program approved by the office of the superintendent of public instruction with a minimum of 720 clock hours of training in medical assisting skills. The documentation must include proof of training in all of the duties identified in RCW 18.360.050(1) and a clinical externship of no less than 160 hours.

(2) Pass a medical assistant certification examination, approved by the secretary, within the preceding five years of submitting an initial application or currently hold a national medical assistant certification with a national examining organization approved by the secretary. A medical assistant certification examination approved by the secretary means an examination that:

(a) Is offered by a medical assistant program that is accredited by the National Commission for Certifying Agencies (NCCA); and

(b) Covers the clinical and administrative duties under RCW 18.360.050(1).

AMENDATORY SECTION (Amending WSR 13-12-045, filed 5/31/13, effective 7/1/13)

WAC 246-827-0240 Medical assistant-certified Administering medications and injections. A medical assistant-certified shall be deemed competent by the delegating health care practitioner prior to administering any ((drug)) medication authorized in this section. ((Drugs)) Medications must be administered under a valid order from the delegating health care practitioner and shall be within the delegating health care practitioner's scope of practice. The order must be in written form or contained in the patient's electronic health care record.

(1) ((Drug)) <u>Medication</u> administration shall not be delegated when:

(a) The ((drug)) <u>medication</u> may cause life-threatening consequences or the danger of immediate and serious harm to the patient;

(b) Complex observations or critical decisions are required;

(c) A patient is unable to physically ingest or safely apply a medication independently or with assistance; or

(d) A patient is unable to indicate awareness that ((he or she is)) they are taking a medication.

(2) To administer medications, the delegator shall ensure a medical assistant-certified receives training concerning: Dosage, technique, acceptable route(s) of administration, appropriate anatomic sites, expected reactions, possible adverse reactions, appropriate intervention for adverse reaction, and risk to the patient. The delegator must ensure a medical assistant-certified is competent to administer the medication.

(3) A medical assistant-certified is prohibited from administering:

(a) Schedule II controlled substances, chemotherapy agents, or experimental drugs; or

(b) Medications through a central intravenous line.

(4) Except as provided in subsection (1) of this section, a medical assistant-certified may administer controlled substances in schedules III, IV, and V or other ((legend drugs)) <u>medications</u> when authorized by the delegating health care practitioner. ((Drugs)) <u>Medications</u> shall be administered only by unit or single dosage or by a dosage calculated and verified by a health care practitioner. For the purposes of this section, a combination or multidose vaccine shall be con-<u>sidered a unit dose</u>. A medical assistant-certified shall only administer ((drugs by)) <u>medications under</u> the level of supervision based on the route as described in subsection (5) of this section.

(5) A medical assistant-certified may only administer medications by the following ((drug)) <u>medication</u> category, route and level of supervision:

((Drug)) <u>Medication</u> Category	Routes Permitted((*))	Level of Supervision Required
Controlled substances, schedule III, IV, and V	Oral, topical, rectal, otic, ophthalmic, or inhaled routes	Immediate supervision
	Intramuscular injections	Immediate supervision
	Subcutaneous, intradermal, ((intramuscular,)) or peripheral intravenous injections	Direct visual supervision

((Drug)) <u>Medication</u> Category	Routes Permitted((*))	Level of Supervision Required
((Other)) Legend drugs (excluding those prohibited by subsection (3)(a) of this section)	((All other routes)) Peripheral intravenous injections	((Immediate)) <u>Direct visual</u> supervision
	All other routes	Immediate supervision
Over-the-counter medications	All routes per manufacturer's instructions	Immediate supervision
	((Peripheral intravenous injections	Direct visual supervision))
Vaccines	Oral, inhaled, subcutaneous, or intramuscular routes	Immediately available or telemedicine supervision

((* A medical assistant-certified is prohibited from administering)

medications through a central intravenous line.

(6) A medical assistant-certified may not start an intravenous line. A medical assistant-certified may interrupt an intravenous line, administer an injection, and restart at the same rate.))

(6) A medical assistant-certified may:

(a) Start an intravenous line for diagnostic or therapeutic purposes under the immediate supervision of a health care practitioner.

(b) Interrupt an intravenous line and restart at the same rate under the immediate supervision of a health care practitioner.

(c) Administer intravenous injections for diagnostic or therapeutic agents under the direct visual supervision of a health care practitioner.

(d) Administer intramuscular injections for the purposes of treating a known or suspected syphilis infection without immediate supervision if a health care practitioner is providing supervision through interactive audio or video telemedicine technology in accordance with RCW 18.360.010 (12) (c) (ii).

NEW SECTION

WAC 246-827-0340 Medical assistant-registered—Administering medications and injections. A medical assistant-registered shall be deemed competent by the delegating health care practitioner prior to administering any medication authorized in this section. Medications must be administered under a valid order from the delegating health care practitioner and shall be within the delegating health care practitioner's scope of practice. The order must be in written form or contained in the patient's electronic health care record.

(1) Medication administration shall not be delegated when:

(a) The medication may cause life-threatening consequences or the danger of immediate and serious harm to the patient;

(b) Complex observations or critical decisions are required;

(c) A patient is unable to physically ingest or safely apply a medication independently or with assistance; or

(d) A patient is unable to indicate awareness that they are taking a medication.

(2) To administer medications, the delegator shall ensure a medical assistant-registered receives training concerning: Dosage, technique, acceptable route(s) of administration, appropriate anatomic sites, expected reactions, possible adverse reactions, appropriate intervention for adverse reaction, and risk to the patient. The delegator must ensure a medical assistant-registered is competent to administer the medication.

(3) A medical assistant-registered is prohibited from administering:

(a) Schedule II controlled substances, chemotherapy agents, or experimental drugs; or

- (b) Medications through a central intravenous line.
- (c) Medications through an intravenous line.
- (d) Medications through intravenous injection.

(4) Except as provided in subsection (1) of this section, a medical assistant-registered may administer controlled substances in schedules III, IV, and V or other medications when authorized by the delegating health care practitioner. Medications shall be administered only by unit or single dosage or by a dosage calculated and verified by a health care practitioner. For the purposes of this section, a combination or multidose vaccine shall be considered a unit dose. A medical assistant-registered shall only administer medications under the level of supervision based on the route as described in subsection (5) of this section.

(5) A medical assistant-registered may only administer medications by the following medications category, route, and level of supervision:

Medication Category	Routes Permitted	Level of Supervision Required
Controlled substances, schedule III, IV, and V	Intramuscular injections	Immediate supervision
Legend drugs (excluding those prohibited by subsection (3)(a) of this section)	Intramuscular injections	Immediate supervision
Over-the- counter medications	All routes per manufacturer's instructions	Immediate supervision
Vaccines	Oral, inhaled, subcutaneous, or intramuscular routes	Immediately available or telemedicine supervision

(6) A medical assistant-registered is prohibited from starting an intravenous line. A medical assistant-registered may interrupt an intravenous line.

(7) A medical assistant-registered may administer intramuscular injections for the purposes of treating a known or suspected syphilis infection without immediate supervision if a health care practitioner is providing supervision through interactive audio or video telemedicine technology in accordance with RCW 18.360.010 (12)(c)(ii).